{"result": "(\"entity\"<|>ANOREXIA NERVOSA<|>EVENT<|>Anorexia Nervosa (AN) is an eating disorder characterized by an intense fear of gaining weight and a distorted body image, leading to restricted food intake and significant weight loss.)\n##\n(\"entity\"<|>BISPHOSPHONATES<|>ORGANIZATION<|>Bisphosphonates are a class of drugs used to prevent the loss of bone density, often prescribed for conditions like osteoporosis.)\n##\n(\"entity\"<|>RIZEDRONATE<|>ORGANIZATION<|>Risedronate is a bisphosphonate medication used to treat osteoporosis and other bone diseases.)\n##\n(\"entity\"<|>TERIPARATIDE<|>ORGANIZATION<|>Teriparatide is a medication used to treat osteoporosis by stimulating bone formation.)\n##\n(\"entity\"<|>17-BETA ESTRADIOL<|>ORGANIZATION<|>17-beta estradiol is a form of estrogen used in hormone replacement therapy to treat various conditions, including osteoporosis.)\n##\n(\"entity\"<|>PROGESTERONE<|>ORGANIZATION<|>Progesterone is a hormone involved in the menstrual cycle and pregnancy, also used in hormone replacement therapy.)\n##\n(\"entity\"<|>GLUCOSE REGULATION<|>EVENT<|>Glucose regulation refers to the processes that maintain blood glucose levels within a normal range, which can be disrupted in patients with anorexia nervosa.)\n##\n(\"entity\"<|>LEPTIN<|>ORGANIZATION<|>Leptin is a hormone that helps to regulate energy balance by inhibiting hunger, which is often altered in patients with anorexia nervosa.)\n##\n(\"entity\"<|>GHRELIN<|>ORGANIZATION<|>Ghrelin is a hormone that stimulates appetite, often elevated in patients with anorexia nervosa.)\n##\n(\"entity\"<|>INSULIN<|>ORGANIZATION<|>Insulin is a hormone that regulates glucose levels in the blood, which can be affected in patients with anorexia nervosa.)\n##\n(\"entity\"<|>MALNUTRITION<|>EVENT<|>Malnutrition is a condition that results from an unbalanced diet or insufficient intake of nutrients, often seen in patients with anorexia nervosa.)\n##\n(\"relationship\"<|>ANOREXIA NERVOSA<|>LEPTIN<|>Patients with anorexia nervosa often present low levels of leptin, which correlates with their body weight<|>8)\n##\n(\"relationship\"<|>ANOREXIA NERVOSA<|>GHRELIN<|>Patients with anorexia nervosa have elevated levels of ghrelin compared to normal weight subjects, indicating a negative energy balance<|>8)\n##\n(\"relationship\"<|>ANOREXIA NERVOSA<|>MALNUTRITION<|>Anorexia nervosa leads to malnutrition, which has various clinical consequences<|>9)\n##\n(\"relationship\"<|>ANOREXIA NERVOSA<|>GLUCOSE REGULATION<|>Anorexia nervosa can disrupt glucose regulation, leading to hypoglycemia<|>7)\n##\n(\"relationship\"<|>ANOREXIA NERVOSA<|>BISPHOSPHONATES<|>Bisphosphonates may be indicated for patients with anorexia nervosa who have low bone mass<|>5)\n##\n(\"relationship\"<|>ANOREXIA NERVOSA<|>RIZEDRONATE<|>Risedronate is a bisphosphonate that may improve bone mass in women with anorexia nervosa<|>5)\n##\n(\"relationship\"<|>ANOREXIA NERVOSA<|>TERIPARATIDE<|>Teriparatide showed significant improvement in bone mass in women with anorexia nervosa<|>6)\n##\n(\"relationship\"<|>ANOREXIA NERVOSA<|>17-BETA ESTRADIOL<|>17-beta estradiol may be considered for adolescents with anorexia nervosa to improve bone mass<|>4)\n##\n(\"relationship\"<|>ANOREXIA NERVOSA<|>PROGESTERONE<|>Progesterone may be used in conjunction with 17-beta estradiol for treatment in adolescents with anorexia nervosa<|>4)\n##\n(\"relationship\"<|>ANOREXIA NERVOSA<|>INSULIN<|>Insulin levels are appropriately low in patients with anorexia nervosa, affecting glucose metabolism<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Asimismo, la administración transdérmica\n---\n                                               Tema 10.     Soporte nutricional en los trastornos de la conducta alimentaria                   159\n\n\n\nde testosterona no ha sido efectiva en mujeres adultas                        quiere de un estudio más amplio. Los pacientes con AN\ncon AN16. En la actualidad se está estudiando si la uti-                      presentan niveles muy bajos de leptina que guardan\nlización conjunta de estrógenos transdérmicos con                             correlación con el peso corporal22. En un estudio, estos\nIGF-1 en adolescentes puede normalizar la masa ósea                           cambios se normalizaron con la recuperación nutricio-\nen estos pacientes.                                                           nal, mientras que en otro no se modificaron con la re-\n   Los bisfosfonatos pueden estar indicados en algunos                        nutrición a corto plazo. Tres estudios han correlaciona-\ncasos, si bien debido a su posible teratogenicidad su                         do la amenorrea de las pacientes con AN con las\nuso en mujeres en edad fértil es más controvertido. En                        alteraciones de la leptina. También se han descrito al-\nun estudio aleatorizado en 32 adolescentes con alen-                          teraciones en la leptina en pacientes con BN.\ndronato durante un año no hubo una mejoría signifi-                              Los pacientes con AN presentan niveles elevados de\ncativa de la masa ósea17. Sin embargo, en un estudio                          ghrelina en comparación con sujetos de peso normal,\naleatorizado con mujeres adultas con risedronato du-                          reflejando el estado de balance energético negativo23.\nrante un año sí se produjo una mejoría significativa de                          Las alteraciones del eje tiroideo en la AN son conse-\nla masa ósea18. A la vista de la evidencia actual, el uso                     cuencia de la malnutrición. Se caracterizan por unos\nde bisfosfonatos se debería restringir a las mujeres con                      niveles en el rango bajo-normal de T4 y TSH, con nive-\nosteoporosis que tengan fracturas.                                            les bajos de T3 y aumento de la rT3. Ello se debe al\n   Otros tratamientos como la calcitonina y el raloxife-                      aumento de la conversión periférica de T4 en rT3 y a la\nno no han mostrado efectos beneficiosos en estos pa-                          disminución de la unión de la T4 a la globulina trans-\ncientes, y el denosumab se ha utilizado solo en algunos\ncasos aislados19. En un reciente estudio aleatorizado el                      portadora de tiroxina. Además, existe una disminución\n\n                                                                              de la respuesta de la TSH a la TRH. Dado que estos\nteriparatide mostró una mejoría importante de la masa                         cambios son adaptativos a la malnutrición y el ayuno,\nósea con tan solo 6 meses de tratamiento en mujeres                           no está indicado el tratamiento con hormonas tiroi-\ncon AN, si bien este fármaco puede incrementar el ries-                       deas. Las consecuencias clínicas incluyen pérdida de\ngo de osteosarcoma en estudios en animales20.                                 pelo, piel seca, hipotermia, bradicardia, hipometabolis-\n   Como conclusión, el tratamiento farmacológico                              mo, etc., que son reversibles tras la renutrición.\ndebe considerarse en mujeres con AN con baja masa                                Otra de las complicaciones de la desnutrición en pa-\nósea y con historia de fracturas si las estrategias de re-                    cientes con AN es la alteración en la regulación de la glu-\ncuperación ponderal no son efectivas a pesar de nues-                         cosa. Estos pacientes pueden presentar hipoglucemia\ntros mejores esfuerzos. Además, la utilización de trata-                      debido a la pérdida de las reservas de glucógeno hepático\nmiento      hormonal      sustitutivo     con   17-beta     estradiol         y al agotamiento de la gluconeogénesis como conse-\ntransdérmico (100 μg/día) y progesterona cíclica (100-                        cuencia de la progresiva pérdida de masa magra. Los ni-\n200 μg/día durante 12 días al mes) puede considerarse                         veles de insulina son apropiadamente bajos y la sensibili-\nen adolescentes con AN con baja masa ósea (a pesar                            dad a la misma es normal. Como consecuencia de estas\nde un adecuado tratamiento nutricional) con el intento                        hipoglucemias       pueden      presentar     crisis  convulsivas     y\nde mejorar la masa ósea en esta edad.                                         coma. Algunos autores han descrito una mayor prevalen-\n   Las manifestaciones endocrinológicas son conse-                            cia de los TCA entre los pacientes con diabetes tipo 1.\ncuencia de una disfunción hipotalámica como respuesta                            Los pacientes con AN presentan frecuentemente re-\nadaptativa del organismo a la desnutrición y el ayuno21.                      traso del crecimiento y del desarrollo como consecuen\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}